ABSTRACT Objective: In Metronomic Chemotherapy (MC) performance of specific surrogate markers plays an important role to obtain the effective treatment. It is very difficult to detect the initial threshold value of surrogate markers to get an idea about optimum dose level of MC for long-term effective treatment. The long-term effective treatment can be obtained through controlling the surrogate markers on continues measured value into a specific range. The long-term effective treatment is defined as long-term recurrence-free survival. During the treatment initiation, many surrogate markers value changes rapidly and those values are time-dependent measurements. The specification of surrogate markers threshold value can only be obtained through the application of ROC curve (AUC), Sensitivity, and Specificity analysis. Material and Methods: The application of ROC curve to detect the timedependent continuous measurement becomes complicated. In this paper, a straightforward Survival Analysis estimator through MCMC iteration for each possible time point measurement is adopted to detect the possible threshold value of surrogate markers. Results: The surrogate markers levels on angiogenesis in Head and Neck Cancer (HNC) patients are considered. Conclusion: The threshold value of the surrogate markers is detected through the formation of ROC curve.
he ROC curves are accepted as having several attractive options in diagnostic medicine. The ROC provides the natural inequity capacity of a test without considering it to any specific threshold. The ROC curves are particularly important for comparing the inequity of different diagnostic markers. It can be adopted as a valid procedure when biomarkers are on completely measured in different occasions. The ROC is free from disease prevalence and hence can be estimated from the experimental study itself. 1 The doses of chemotherapy selected in clinical practice are routinely derived from the maximum tolerable dose(MTD) approaches. It is believed that an increase in dose will lead to an increase in tumor response. The dose selected for phase 2 and further studies is one dose level below the MTD level in Phase I studies. [2] [3] [4] However, this conventional dosing of chemotherapy has routinely compromised the QOL of patients and may lead to a selection of chemo-resistant clones. [5] [6] [7] Chemo-resistance and toxic effects are the major problems in chemotherapy drug administration. A new modality of drug administration has emerged is known as "metronomic chemotherapy (MC)". It has been suggested as an alternative strategy to overcome such effects. It provides repeated administration of conventional chemotherapeutic agents at very low doses. It gives a rare chance of developing acquired drug resistance. 8 Studies of tumor endothelial cells through pharmacogenomic and pharmacoproteomic effects are required to be performed to explore the information about an effective surrogate marker(SM) to provide the best treatment combinations for each tumor type and patient population. 9 A key scientific question is whether the SM's specific level measured during MC initiations can contribute towards long-term effective treatment. The precision through the sensitivity and specificity of SM's continuous measurement are required to be established for specific MC dose level on site wise tumor growth. The aim of this manuscript is to extend the concepts of sensitivity and specificity of time-dependent continuous measurement, allowing classification of diagnostic accuracy for MC treatment outcomes.
MATERIAL AND METHODS
The survival function is defined with
The term n is the total sample size and R( ( ) ) is the individual at risk at time point .
It is assumed with
The number of order times (recurrence and censored) is defined with m. The process of iteration started with known value from ( ($) )).
It is assumed that the number of cancer patients recurred are presented with ordered times follows the binomial distribution
The probability of recurrence and individual at risk are defined as q 
The posterior mean of ( ( ) )) is utilized to get the recurrence probability.
The conditional probabilities is formed with
The censored observations is defined as
and q5&'(~beta(0.01,0.01)
The number at risk at time i is R 
The dose of MC is separated with levels and defined as group1 and group2.
The expected number of events for group1 and group2 are defined with
The sum of observed minus and expected difference for group1 and group2 is defined as c = ∑ (% − X )and
It is assumed that the probability of a recurrence for both the treated group is equal.
The Bayesian likelihood ratio is defined as 
LIKELIHOOD
The cumulative hazard function H(t) is defined as
The function S(t) is the survival function. 10, 11 The cumulative hazard function H(t) is defined with
Where
This cumulative hazard function H(t) is more appropriate for distribution with continuous measurement. The prior distribution in this setting is defined as
where c(s)dH*(s) and c(s)(1-dH*(s)) represents the scale and shape parameters with beta distribution.
The distribution of H(s) is approximated with beta distribution with finite range. It is promising to work with beta distribution for the baseline cumulative hazard appropriated through a Cox model with time continuous measurement. 12 However it is more convenient to work with categorized version of the beta distribution. 13, 14 The corresponding likelihood is defined below. Suppose the Cox model is defined as
The term hk is the baseline hazard rate for the interval Ik=(sk-1, sk].
The likelihood is defined as
where h=(h1, h2,.....,hJ)'.The independent beta priors for the hk's are assumed with ℎ~? 5 $y • $y , 5 $y (1 − • $y ) and those are independent for k=1,2, . . . , J.
It is assumed that hk are independent from other priors. The continuous-time point measurement has been considered to obtain the beta distribution approximated for hk. It can perform well with separated interval Ik.
The prior density of h is defined with
Further it is assumed with?~€(• $ , ‚ $ ) as independent of h.
The joint posterior of (?, ℎ) is defined with
The hazard hj is defined with
Therefore, the survival curve is defined as
The prior distribution of hj is obtained with The term C 0j is adopted to measure the confidence interval approximated with prior mean α 0j of the hazard rate hj in Ij.
The posterior distribution of the hj is obtained with 
ROC, SENSITIVITY AND SPECIFICITY
Receiver operating characteristic (ROC) curves are widely adopted to measure the performance of diagnostic tools and prognostic biomarkers. Suppose the continuous SM measurements after administration of MC are considered to identify Head and Neck(HNC) patients will recur or not. The measurement of SM is performed through the specific diagnostic test. Let Y be the value of the SM measurements. It is assumed with a continuous random variable having distribution FR in the recurred and FNR in the non-recurred HNC patients. Further, it is assumed that the SM tends to be increased in the recurred patients. The given threshold value c, that is Y>c is considered.
However, the lower values of c tend to low falsenegative rates but high false-positive rates. However, high values of c lead to high false-negative rates but low false-positive rates. The ROC curve is used to make tradeoffs between true and false positives on different combination of discrimination on threshold value of c. The ROC can be expressed with curve by
The method explained above is simple and suitable when all HNC patients are observed for the same length of time. It is to be noted that the MC administration and corresponding measurement of SM are time dependent. It is possible to fit the model through follow-up time measurements. It can be estimated through survival analysis to capture the variation with time. It takes consideration of time-dependent ROC, AUC, sensitivity and specificity. The term AUC(t) provides the probability that a person with HNC patients with recurrence by time t has a higher value of SM measurements than an HNC patients with no recurrence by time t. Let the HNC patients "i" with risk of having recurrence before the time τ is q• > 5 ' r. The threshold value of the SM is defined as ciτ. The sensitivity (se) and the specificity (sp) of the SM is defined as Xi for the prediction of the failure "i", i.e.
(• > 5 ' | ≤ ')and (• ≤ 5 ' | > ') with
The probability density function gi(xi) is used for the continuous SM value with xi. The sensitivity is defined as the probability of being at risk given that a failure "i" occurs before time τ.
The specificity is defined as the probability of not being at risk given that a failure "i" does not occur before time τ. It is very important to be considered about the selection of τ during the observation duration where the sufficient number of patients will be present to get the predicted results.
APPLICATION ON METRONOMIC CHEMOTHERAPY DATA
The clinical goal is to find the optimum Biological Dose of MC of two dose level i.e. 15mg/m 2 and 10mg/m 2 for predicting the long term nonrecurrence rate among HNC patients. The specific idea is to study the level of serum creatinine levels (SCR) and define the threshold value for a duration of administration of MC on 1,3,5,7,9 and 11th weeks. The maximum days to monitor the level of SM is specified as τ=80 days. A total of 63 patients were separated for MC therapy of dose level 15mg/m 2 (termed as group1) and 10 mg/m 2 (termed as group2).A total of 11 patient's SM value were observed with more than threshold value in group1 and a total of 19 patients in group2.However, during the MC therapy, the schedule has been finalized for each patient with individual specific prognostic function. It is assumed that the level of SM will not be more than the threshold value at any point of time. The probabilities of an event for 80 days for individuals are detailed in Table 1 . The proposed method has been illustrated on MC therapy. The results are detailed in Table 1 and corresponding data explored in Figure 1 .
RESULT AND DISCUSSION
The initial study report on MC presented and the overall survival (OS) was also increased significantly in the MCT arm. 16 In a case of OBD, the widely adopted method is trinomial continual reassessment, where the highest probability of toxic effect is considered. 16 Low-dose chemotherapy drugs are more effective to suppress tumors by restraining tumor vessel growth and preventing the repair of damaged vascular endothelial cells. 17 A high-dose chemotherapy drug like Cisplatin contributes to serious side effects. 18 The target of MC therapy is the vascular endothelial cells. 19 The growth of new vessels for a long-term survival time treated with traditional maximum tolerated dose (MTD) through high-dose chemotherapy has been confirmed. 20 The antiangiogenic plays the important role as clinical potential. 21 The metastasis and the growth of tumor cells depend on neovascularization. 20 The anti-tumor drugs could cause inhibition of tumor neovascularity. 23 The SCR have emerged as a promising candidate surrogate marker to assess the efficacy of antiangiogenic therapies. 22, [24] [25] [26] [27] The low-dose chemotherapy drugs, as one-tenth of the MTD, administered continuously and frequently, could selectively suppress vessel growth in tumor tissues and prevent the repair of damaged vascular endothelial cells (VECs). 18 It is expected that this above-mentioned methods will be useful for OBD detection in MC trials. The application of time-dependent AUC was adopted through consideration of censored survival data 1 . In this work the AUC is presented as a function of time to detect the OBD. The estimates of AUC obtained through MCMC iterations. The AUC with time function is estimated through survival function. Recently, the Bayesian counterpart as a choice computation approach is also selected and found feasible and suitable. 28 The comparison of ROC curve estimators for a time-dependent outcome with marker-dependent censoring has also been attempted. 29, 30 The marker specific threshold value has been obtained based on a performance of AUC. In this aspect another definition of sensitivity and specificity coined to discriminate the patients performance with failure up to time τ. The goal of this work is to present an approach to discriminate the patients according to their chance of appearance of recurrence based on threshold value of SM at time point τ on i th individual. The corresponding ROC curve at time τ, called ROCi(τ) obtained through relation plot of sensitivity and specificity in different threshold value i.e. ciτ.
The accuracy of the SM to predict the presence/absence of the failure i is measured by the area under the ROCi(τ ) curve. The performance of AUCi(τ ) obtained through posterior estimates. The posterior estimated generated through 20,000 iterations with 5,000 burns in refreshment. The 95% credible interval of AUC obtained are given in Table 2 . The threshold value of SM will provide us opportunity to predict the individual's chances of appearance of recurrence during long-term follow-up and to detect the corresponding true value of AUC. 
